Xeris Biopharma (NASDAQ:XERS) and AleAnna (NASDAQ:ANNA) Financial Review

AleAnna (NASDAQ:ANNA) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares AleAnna and Xeris Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AleAnna	-46.01%	-14.90%	-8.74%
Xeris Biopharma	0.19%	-3.01%	0.16%

Volatility & Risk

AleAnna has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Institutional and Insider Ownership

38.1% of AleAnna shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 42.9% of AleAnna shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares AleAnna and Xeris Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AleAnna	$1.42 million	166.63	-$12.34 million	$0.04	88.75
Xeris Biopharma	$291.85 million	3.38	-$54.84 million	($0.10)	-59.40

AleAnna has higher earnings, but lower revenue than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for AleAnna and Xeris Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AleAnna	1	0	0	0	1.00
Xeris Biopharma	1	2	5	0	2.50

Xeris Biopharma has a consensus target price of $10.08, indicating a potential upside of 69.75%. Given Xeris Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than AleAnna.

Summary

Xeris Biopharma beats AleAnna on 9 of the 14 factors compared between the two stocks.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.